American Federation for Aging Research

SuperAgers Family Study Reaches First National Recruitment Milestone Using Digital Methods Powered by Vibrent Health’s Research Software

Retrieved on: 
Tuesday, May 9, 2023

The SuperAgers Family Study aims to collect data from 10,000 people, primarily individuals 95 and older, but also including their children and children’s spouses.

Key Points: 
  • The SuperAgers Family Study aims to collect data from 10,000 people, primarily individuals 95 and older, but also including their children and children’s spouses.
  • By exceeding their first recruitment milestone, the SuperAgers study demonstrates that digital approaches can engage aging populations.
  • “For those with less comfort, our recruitment of superager offspring in the study helps to foster compliance in superagers using digital methods.
  • As health research becomes increasingly digital, family-based datasets represent a robust, promising area of precision health research.”

Hevolution Foundation Geroscience Research Opportunities (HF-GRO) Awards Unveiled, with a Budget of up to $115M Over Five Years

Retrieved on: 
Friday, May 5, 2023

Hevolution Foundation , a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science, is launching a new grants program, “Hevolution Foundation - Geroscience Research Opportunities” (HF-GRO).

Key Points: 
  • Hevolution Foundation , a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science, is launching a new grants program, “Hevolution Foundation - Geroscience Research Opportunities” (HF-GRO).
  • HF-GRO will provide funding for pre-clinical research in aging biology and geroscience in the United States, Canada, and Europe.
  • The program has a budget of up to $25 million for the remainder of 2023, and up to $115 million over five years.
  • The American Federation for Aging Research ( AFAR ) is providing programmatic support for the HF-GRO program for Hevolution Foundation.

Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Recipients Announced

Retrieved on: 
Tuesday, April 18, 2023

Hevolution Foundation and the American Federation for Aging Research ( AFAR ) are pleased to announce the inaugural Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipients.

Key Points: 
  • Hevolution Foundation and the American Federation for Aging Research ( AFAR ) are pleased to announce the inaugural Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipients.
  • Eighteen three-year awards of $375,000 each, for a total of $6.75 Million, have been granted to support research projects in the basic biology of aging or geroscience, a research paradigm based on addressing the biology of aging and age-related disease to promote healthy aging.
  • “Some of the biggest breakthroughs in aging research today were funded first through AFAR’s grants for promising early career researchers.
  • The Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research will significantly boost support for junior faculty worldwide,” noted Stephanie Lederman, EdM, Executive Director, AFAR.

Hevolution Foundation Matches Funding for Impetus Grants to Accelerate Research in Neglected Areas of Healthspan Science

Retrieved on: 
Wednesday, August 31, 2022

Hevolution Foundation , a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science announces the results of $2 Million in matching funding for a program from Impetus Grants , a non-profit science funding organization focused on longevity research.

Key Points: 
  • Hevolution Foundation , a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science announces the results of $2 Million in matching funding for a program from Impetus Grants , a non-profit science funding organization focused on longevity research.
  • Building on our just-announced partnership with the American Federation for Aging Research (AFAR), we are pleased that our $2 Million in matching funds for Impetus Grants has helped enable the organization to fund 14 innovative academic research projects in healthspan science and related fields, commented Felipe Sierra, PhD, Chief Scientific Officer.
  • From causality of methylation clocks to in vivo measurements of multiple aging mechanisms to in situ genome-scale measurements of multiple aging mechanisms, and a variety of other areas, this is important, healthspan-oriented research that has typically been underfunded.
  • The total grant funding of $4 Million was awarded to 14 investigators conducting research in a variety of disciplines and stages of healthspan science.

Hevolution Foundation and AFAR Announce New Investigator Awards in Aging Biology and Geroscience Research

Retrieved on: 
Wednesday, August 31, 2022

Representing Hevolution Foundations first deployment of capital into aging research, the Hevolution /AFAR New Investigator Awards in Aging Biology and Geroscience Research will provide up to 18 three-year awards of US $375,000 each.

Key Points: 
  • Representing Hevolution Foundations first deployment of capital into aging research, the Hevolution /AFAR New Investigator Awards in Aging Biology and Geroscience Research will provide up to 18 three-year awards of US $375,000 each.
  • The awards will support research projects into the basic biology of aging and/or geroscience, a research paradigm focused on the biology of aging and the biology of age-related disease.
  • Additionally, Hevolution Foundation will establish a Conference Fund, managed by AFAR, to support conferences and scientific meetings on aging research and geroscience.
  • For more information on the New Investigator Awards in Aging Biology and Geroscience, the Conference Fund, and all AFAR grant programs, please visit http://www.afar.org/funding-opportunities .

KRTL Holding Group Inc Welcomes Dr. Malcolm A. Leissring as Chief Science Officer of KRTL Biotech, Inc.

Retrieved on: 
Thursday, August 18, 2022

Lakewood, CO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC: KRTL) is pleased to announce its wholly owned subsidiary, KRTL Biotech, Inc., an international research, and development company, has appointed Dr. Malcolm A. Leissring as its founding Chief Science Officer.

Key Points: 
  • Lakewood, CO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC: KRTL) is pleased to announce its wholly owned subsidiary, KRTL Biotech, Inc., an international research, and development company, has appointed Dr. Malcolm A. Leissring as its founding Chief Science Officer.
  • Dr. Leissring is an internationally recognized neuroscientist with expertise in the molecular pathogenesis of Alzheimer 's disease and diabetes, along with extensive expertise in drug discovery and drug development.
  • The Company operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp., with precision and excellence and continues to create and strengthen the KRTL reputation.
  • This allows KRTL Holding Group, Inc. to capitalize on any range of investment opportunities.

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Retrieved on: 
Monday, August 8, 2022

MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research.

Key Points: 
  • Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells.
  • Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018.
  • A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming.
  • His Stanford University lab pioneered the development of a new paradigm for treating aging and age-related diseases.

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Retrieved on: 
Monday, August 8, 2022

MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research.

Key Points: 
  • Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells.
  • Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018.
  • A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming.
  • His Stanford University lab pioneered the development of a new paradigm for treating aging and age-related diseases.

Known Medicine Appoints Kristen Fortney to Advisory Board

Retrieved on: 
Monday, April 11, 2022

Known Medicine is pleased to announce it has appointed Kristen Fortney, PhD, as an advisor.

Key Points: 
  • Known Medicine is pleased to announce it has appointed Kristen Fortney, PhD, as an advisor.
  • Dr. Fortney brings her personal experience as the CEO of a clinical stage, platform-based drug discovery company to our advisory board.
  • Im excited to bring my expertise evaluating and developing drugs informed by data-driven investigations to Known Medicine, said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs.
  • Known Medicine merges cancer biology and machine learning to understand drug efficacy and patient-specific predictors of response.

Agtech Appoints Leading Harvard Trained Medical Expert as Chief Science Officer

Retrieved on: 
Thursday, December 9, 2021

CALIFORNIA, Newport Beach, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Agtech Global International, Inc. (Agtech) (name change to Galexxy Holdings Inc. in process) (OTC Pink: AGGL) is pleased to announce the appointment of Dr. Malcolm A. Leissring as its Chief Science Officer (CSO) effective January 1, 2022.

Key Points: 
  • CALIFORNIA, Newport Beach, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Agtech Global International, Inc. (Agtech) (name change to Galexxy Holdings Inc. in process) (OTC Pink: AGGL) is pleased to announce the appointment of Dr. Malcolm A. Leissring as its Chief Science Officer (CSO) effective January 1, 2022.
  • This appointment follows Agtechs recent agreement to acquire NooMeds, LLC., a company formed by Dr. Leissring to market A.L.Z.
  • Defense, a scientifically tested dietary supplement shown to prevent memory problems in laboratory models of Alzheimers disease.
  • He conducted his postdoctoral training at Harvard Medical School in the laboratory of Dennis J. Selkoe, M.D., one of the worlds leading researchers in Alzheimers disease.